Suppr超能文献

miR-1298通过抑制粘着斑激酶(FAK)和层粘连蛋白β3(LAMB3)来抑制突变型KRAS驱动的肿瘤生长。

miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.

作者信息

Zhou Ying, Dang Jason, Chang Kung-Yen, Yau Edwin, Aza-Blanc Pedro, Moscat Jorge, Rana Tariq M

机构信息

Program for RNA Biology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.

Program for RNA Biology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California. Department of Pediatrics, University of California San Diego, La Jolla, California.

出版信息

Cancer Res. 2016 Oct 1;76(19):5777-5787. doi: 10.1158/0008-5472.CAN-15-2936.

Abstract

Global miRNA functional screens can offer a strategy to identify synthetic lethal interactions in cancer cells that might be exploited therapeutically. In this study, we applied this strategy to identify novel gene interactions in KRAS-mutant cancer cells. In this manner, we discovered miR-1298, a novel miRNA that inhibited the growth of KRAS-driven cells both in vitro and in vivo Using miR-TRAP affinity purification technology, we identified the tyrosine kinase FAK and the laminin subunit LAMB3 as functional targets of miR-1298. Silencing of FAK or LAMB3 recapitulated the synthetic lethal effects of miR-1298 expression in KRAS-driven cancer cells, whereas coexpression of both proteins was critical to rescue miR-1298-induced cell death. Expression of LAMB3 but not FAK was upregulated by mutant KRAS. In clinical specimens, elevated LAMB3 expression correlated with poorer survival in lung cancer patients with an oncogenic KRAS gene signature, suggesting a novel candidate biomarker in this disease setting. Our results define a novel regulatory pathway in KRAS-driven cancers, which offers a potential therapeutic target for their eradication. Cancer Res; 76(19); 5777-87. ©2016 AACR.

摘要

全球微小RNA功能筛选可为识别癌细胞中的合成致死相互作用提供一种策略,这些相互作用可能具有治疗价值。在本研究中,我们应用该策略来识别KRAS突变癌细胞中的新型基因相互作用。通过这种方式,我们发现了miR-1298,一种新型微小RNA,它在体外和体内均能抑制KRAS驱动的细胞生长。利用miR-TRAP亲和纯化技术,我们确定酪氨酸激酶FAK和层粘连蛋白亚基LAMB3是miR-1298的功能靶点。沉默FAK或LAMB3可重现miR-1298在KRAS驱动的癌细胞中表达的合成致死效应,而这两种蛋白的共表达对于挽救miR-1298诱导的细胞死亡至关重要。突变型KRAS可上调LAMB3而非FAK的表达。在临床标本中,LAMB3表达升高与具有致癌性KRAS基因特征的肺癌患者较差的生存率相关,提示在这种疾病背景下有一个新的候选生物标志物。我们的研究结果定义了KRAS驱动的癌症中的一种新型调控途径,为其根除提供了潜在的治疗靶点。《癌症研究》;76(19);5777 - 5787。©2016美国癌症研究协会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d86/5155639/d366470aae71/nihms807138f1.jpg

相似文献

8
PKC Is Required for KRAS-Driven Lung Tumorigenesis.PKC 对于 KRAS 驱动的肺肿瘤发生是必需的。
Cancer Res. 2020 Dec 1;80(23):5166-5173. doi: 10.1158/0008-5472.CAN-20-1300. Epub 2020 Sep 29.

引用本文的文献

4
Therapeutic Targets of KRAS in Colorectal Cancer.KRAS在结直肠癌中的治疗靶点
Cancers (Basel). 2021 Dec 11;13(24):6233. doi: 10.3390/cancers13246233.
7
Inhibition of miR-1298-5p attenuates sepsis lung injury by targeting SOCS6.抑制 miR-1298-5p 通过靶向 SOCS6 减轻脓毒症肺损伤。
Mol Cell Biochem. 2021 Oct;476(10):3745-3756. doi: 10.1007/s11010-021-04170-w. Epub 2021 Jun 7.

本文引用的文献

2
The landscape of long noncoding RNAs in the human transcriptome.人类转录组中的长链非编码RNA图谱
Nat Genet. 2015 Mar;47(3):199-208. doi: 10.1038/ng.3192. Epub 2015 Jan 19.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验